BioMarin Pharmaceutical Inc. (BMRN) Profit Margins
Over the twelve months to 2026-06-30, BioMarin Pharmaceutical Inc. (BMRN) had gross margin 76.1%, operating margin 4.4%, net margin 2.1%, free cash flow margin 21.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BMRNBioMarin Pharmaceutical Inc.Follow BMRN — free
—
Price chart with a free account
- Market cap
- 10.8B
- P/E TTM
- 151.2
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
| Line | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 81.3% | 81.0% | 81.7% | 83.9% | 83.7% | 82.9% | 81.2% | 81.6% | 78.9% | 78.9% | 71.8% | 74.5% | 76.0% | 78.0% | 79.7% | 77.7% | 76.1% | |
| Operating margin | 0.1% | -7.7% | -22.0% | -28.4% | -12.4% | -12.4% | -71.9% | -1.1% | -8.3% | -5.9% | -2.3% | -4.5% | 7.7% | 7.7% | 17.0% | 12.7% | 4.4% | |
| Net margin | 54.7% | -12.2% | -22.8% | -32.2% | -17.9% | -19.3% | -56.4% | -8.9% | -5.2% | -1.4% | 45.9% | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% | 2.1% | |
| FCF margin | -8.2% | -12.4% | -5.4% | -22.8% | -25.0% | -50.2% | -33.7% | -15.8% | -8.3% | -5.7% | -1.6% | 11.3% | 2.6% | 2.6% | 17.1% | 22.5% | 21.7% |
USD billions · SEC XBRL
BioMarin Pharmaceutical Inc. — questions
- What is BioMarin Pharmaceutical Inc.'s gross margin?
- 76.1% over the twelve months to 2026-06-30.
- What is BioMarin Pharmaceutical Inc.'s operating margin?
- 4.4% over the twelve months to 2026-06-30.
- What is BioMarin Pharmaceutical Inc.'s net profit margin?
- 2.1% over the twelve months to 2026-06-30.
Every figure on this page comes from BioMarin Pharmaceutical Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.